Compare Stocks

Date Range: 

 Acceleron PharmaFate TherapeuticsExelixisDenali TherapeuticsNeurocrine Biosciences
SymbolNASDAQ:XLRNNASDAQ:FATENASDAQ:EXELNASDAQ:DNLINASDAQ:NBIX
Price Information
Current Price$122.81$86.19$16.73$63.90$98.52
50-Day Moving Average$125.22$81.94$20.80$68.74$97.16
52-Week Low$85.58$29.37$16.24$22.36$86.02
52-Week High$146.15$121.16$27.35$93.94$127.19
MarketRank™
Overall Score1.81.61.91.52.4
Analysis Score3.53.43.43.44.3
Community Score3.03.02.62.53.6
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.60.01.90.02.5
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$154.00$113.25$30.75$80.86$123.47
% Upside from Price Target25.40% upside31.40% upside83.80% upside26.54% upside25.32% upside
Trade Information
Market Cap$7.45 billion$8.11 billion$5.24 billion$7.74 billion$9.32 billion
Beta0.361.671.071.920.76
Average Volume322,316842,9963,572,127673,709665,773
Sales & Book Value
Annual Revenue$92.52 million$31.43 million$987.54 million$335.66 million$1.05 billion
Price / Sales80.57257.885.3123.078.91
CashflowN/AN/A$0.38 per share$0.66 per share$4.67 per share
Price / CashN/AN/A43.4697.0821.08
Book Value$14.19 per share$4.41 per share$6.06 per share$9.59 per share$11.99 per share
Price / Book8.6519.542.766.668.22
Profitability
Net Income$-166,030,000.00$-173,390,000.00$111.78 million$71.14 million$407.30 million
EPS($2.92)($1.52)$0.35$0.63$4.16
Trailing P/E RatioN/AN/A83.65277.8424.03
Forward P/E RatioN/AN/A19.68N/A24.51
P/E GrowthN/AN/A1.28N/AN/A
Net Margins-158.11%-461.69%6.28%17.02%38.45%
Return on Equity (ROE)-23.81%-26.48%3.47%6.36%40.53%
Return on Assets (ROA)-21.95%-18.62%3.05%4.75%24.37%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.27%
Current Ratio14.81%8.50%6.72%26.22%5.71%
Quick Ratio14.81%8.50%6.61%26.22%5.55%
Ownership Information
Institutional Ownership Percentage88.08%98.69%82.29%65.89%99.71%
Insider Ownership Percentage1.70%18.58%3.30%17.00%4.30%
Miscellaneous
Employees312314773311865
Shares Outstanding60.70 million94.04 million313.39 million121.19 million94.55 million
Next Earnings Date8/5/2021 (Estimated)8/4/2021 (Confirmed)8/5/2021 (Confirmed)8/6/2021 (Estimated)8/3/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Zacks Investment ResearchNeurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Zacks Investment Research
marketbeat.com - July 24 at 2:08 AM
Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)
finance.yahoo.com - July 22 at 2:20 PM
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial ResultsNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
finance.yahoo.com - July 19 at 6:40 PM
HC Wainwright Reiterates Buy Rating for Neurocrine Biosciences (NASDAQ:NBIX)HC Wainwright Reiterates Buy Rating for Neurocrine Biosciences (NASDAQ:NBIX)
americanbankingnews.com - July 16 at 11:10 AM
Financial Comparison: INmune Bio (NASDAQ:INMB) and Neurocrine Biosciences (NASDAQ:NBIX)Financial Comparison: INmune Bio (NASDAQ:INMB) and Neurocrine Biosciences (NASDAQ:NBIX)
americanbankingnews.com - July 11 at 5:16 AM
Technical Short Put Spread Fade the Dip Trade and Trigger in Neurocrine Biosciences IncTechnical Short Put Spread Fade the Dip Trade and Trigger in Neurocrine Biosciences Inc
cmlviz.com - July 11 at 12:36 AM
Neurocrine Biosciences to Participate at the William Blair Biotech Focus ConferenceNeurocrine Biosciences to Participate at the William Blair Biotech Focus Conference
finance.yahoo.com - July 8 at 7:16 PM
Neurocrine Biosciences - NBIX - Low Risk Biotech X10 StockNeurocrine Biosciences - NBIX - Low Risk Biotech X10 Stock
marketoracle.co.uk - July 5 at 10:28 PM
Sarepta, Vertex, Neurocrine: Theres Deep Value In These Beaten Down Healthcare StocksSarepta, Vertex, Neurocrine: There's Deep Value In These Beaten Down Healthcare Stocks
nasdaq.com - July 2 at 7:09 AM
First Week of February 2022 Options Trading For Neurocrine Biosciences (NBIX)First Week of February 2022 Options Trading For Neurocrine Biosciences (NBIX)
nasdaq.com - June 21 at 1:14 PM
Subdued Growth No Barrier To Neurocrine Biosciences, Inc.s (NASDAQ:NBIX) PriceSubdued Growth No Barrier To Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price
finance.yahoo.com - June 21 at 1:14 PM
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Is Currently -35.56% Below Its 52-Week High, But Downside Potential Could Surprise You.Neurocrine Biosciences Inc. (NASDAQ:NBIX) Is Currently -35.56% Below Its 52-Week High, But Downside Potential Could Surprise You.
marketingsentinel.com - June 19 at 6:21 PM
Neurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIXNeurocrine Biosciences Breaks Above 200-Day Moving Average - Bullish for NBIX
nasdaq.com - June 17 at 3:05 PM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Investors Are Less Pessimistic Than ExpectedNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Investors Are Less Pessimistic Than Expected
nasdaq.com - June 14 at 1:47 PM
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare ConferenceNeurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
finance.yahoo.com - June 1 at 7:42 PM
Neurocrine Biosciences Inc (NBIX): Price Now Near $95.49; Daily Chart Shows Downtrend on 100 Day BasisNeurocrine Biosciences Inc (NBIX): Price Now Near $95.49; Daily Chart Shows Downtrend on 100 Day Basis
etfdailynews.com - June 1 at 2:41 PM
Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIXNeurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX
seekingalpha.com - May 26 at 10:21 AM
Neurocrine Biosciences Inc (NBIX): Price Now Near $96.17; Daily Chart Shows Downtrend on 100 Day BasisNeurocrine Biosciences Inc (NBIX): Price Now Near $96.17; Daily Chart Shows Downtrend on 100 Day Basis
etfdailynews.com - May 21 at 2:20 PM
Partner Fund Management, L.P. Buys Neurocrine Biosciences Inc, Myriad Genetics Inc, Baxter ...Partner Fund Management, L.P. Buys Neurocrine Biosciences Inc, Myriad Genetics Inc, Baxter ...
gurufocus.com - May 18 at 6:59 PM
Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare ConferenceNeurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference
finance.yahoo.com - May 11 at 5:31 PM
Robert W. Baird Stick to Their Buy Rating for NeurocrineRobert W. Baird Stick to Their Buy Rating for Neurocrine
investing.com - May 9 at 9:40 AM
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call TranscriptNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 7:04 AM
Needham Reaffirms Their Hold Rating on Neurocrine (NBIX)Needham Reaffirms Their Hold Rating on Neurocrine (NBIX)
smarteranalyst.com - May 6 at 4:03 PM
Neurocrine Biosciences, Inc. 2021 Q1 - Results - Earnings Call PresentationNeurocrine Biosciences, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 5 at 10:51 PM
Neurocrine: Q1 Earnings SnapshotNeurocrine: Q1 Earnings Snapshot
sfgate.com - May 5 at 6:56 PM
Neurocrine Biosciences Inc Q1 adjusted earnings Miss EstimatesNeurocrine Biosciences Inc Q1 adjusted earnings Miss Estimates
nasdaq.com - May 5 at 6:56 PM
DateCompanyBrokerageAction
7/19/2021Acceleron PharmaWolfe Research
Initiated Coverage
7/16/2021Neurocrine BiosciencesHC Wainwright
Reiterated Rating
7/15/2021Denali TherapeuticsHC Wainwright
Reiterated Rating
7/9/2021Fate TherapeuticsStifel Nicolaus
Reiterated Rating
6/29/2021ExelixisHC Wainwright
Reiterated Rating
6/29/2021ExelixisOppenheimer
Lower Price Target
6/28/2021ExelixisNeedham & Company LLC
Lower Price Target
6/27/2021Acceleron PharmaSVB Leerink
Reiterated Rating
6/24/2021Acceleron PharmaOppenheimer
Boost Price Target
6/15/2021Acceleron PharmaSVB Leerink
Reiterated Rating
6/15/2021ExelixisHC Wainwright
Initiated Coverage
6/7/2021Fate TherapeuticsHC Wainwright
Upgrade
5/18/2021Denali TherapeuticsUBS Group
Initiated Coverage
5/18/2021Neurocrine BiosciencesThe Goldman Sachs Group
Initiated Coverage
5/14/2021Fate TherapeuticsWedbush
Downgrade
5/7/2021Fate TherapeuticsWedbush
Upgrade
5/6/2021Neurocrine BiosciencesWedbush
Lower Price Target
5/6/2021Neurocrine BiosciencesOppenheimer
Lower Price Target
5/6/2021Neurocrine BiosciencesMorgan Stanley
Lower Price Target
5/6/2021Neurocrine BiosciencesSVB Leerink
Lower Price Target
5/6/2021Neurocrine BiosciencesBarclays
Upgrade
5/3/2021Neurocrine BiosciencesMizuho
Lower Price Target
4/26/2021Fate TherapeuticsJefferies Financial Group
Initiated Coverage
4/26/2021Neurocrine BiosciencesMizuho
Lower Price Target
4/19/2021ExelixisMorgan Stanley
Lower Price Target
4/19/2021Neurocrine BiosciencesMorgan Stanley
Boost Price Target
4/12/2021Neurocrine BiosciencesWedbush
Lower Price Target
3/30/2021ExelixisCredit Suisse Group
Initiated Coverage
3/29/2021Acceleron PharmaThe Goldman Sachs Group
Reiterated Rating
3/29/2021Acceleron PharmaSVB Leerink
Reiterated Rating
3/23/2021Acceleron PharmaSVB Leerink
Downgrade
3/22/2021Acceleron PharmaThe Goldman Sachs Group
Reiterated Rating
3/12/2021Fate TherapeuticsSVB Leerink
Boost Price Target
3/11/2021Acceleron PharmaWolfe Research
Initiated Coverage
3/11/2021ExelixisWolfe Research
Initiated Coverage
3/5/2021Neurocrine BiosciencesRobert W. Baird
Reiterated Rating
3/4/2021Fate TherapeuticsWedbush
Reiterated Rating
3/4/2021Fate TherapeuticsWells Fargo & Company
Boost Price Target
3/4/2021Denali TherapeuticsHC Wainwright
Boost Price Target
3/1/2021Acceleron PharmaCitigroup
Boost Price Target
2/26/2021Acceleron PharmaPiper Sandler
Boost Price Target
2/26/2021Acceleron PharmaMorgan Stanley
Boost Price Target
2/26/2021Acceleron PharmaSVB Leerink
Boost Price Target
2/26/2021Fate TherapeuticsTruist
Boost Price Target
2/26/2021Fate TherapeuticsBank of America
Initiated Coverage
2/26/2021Fate TherapeuticsWedbush
Downgrade
2/26/2021Denali TherapeuticsHC Wainwright
Reiterated Rating
2/25/2021Fate TherapeuticsRoth Capital
Boost Price Target
2/25/2021Fate TherapeuticsCantor Fitzgerald
Boost Price Target
2/25/2021Fate TherapeuticsMizuho
Boost Price Target
2/17/2021Fate TherapeuticsPiper Sandler
Boost Price Target
2/16/2021ExelixisPiper Sandler
Boost Price Target
2/11/2021Fate TherapeuticsCitigroup
Downgrade
2/10/2021Denali TherapeuticsCantor Fitzgerald
Upgrade
2/5/2021Neurocrine BiosciencesMizuho
Boost Price Target
2/1/2021Neurocrine BiosciencesRaymond James
Initiated Coverage
1/29/2021Acceleron PharmaJPMorgan Chase & Co.
Boost Price Target
1/27/2021Fate TherapeuticsHC Wainwright
Reiterated Rating
1/26/2021Neurocrine BiosciencesWilliam Blair
Reiterated Rating
1/25/2021Fate TherapeuticsBMO Capital Markets
Boost Price Target
1/21/2021Neurocrine BiosciencesCanaccord Genuity
Reiterated Rating
1/19/2021Acceleron PharmaRaymond James
Boost Price Target
1/19/2021Acceleron PharmaHC Wainwright
Boost Price Target
1/19/2021Fate TherapeuticsOppenheimer
Reiterated Rating
1/15/2021Fate TherapeuticsBarclays
Boost Price Target
1/15/2021ExelixisWilliam Blair
Reiterated Rating
1/8/2021Denali TherapeuticsJPMorgan Chase & Co.
Initiated Coverage
12/29/2020Neurocrine BiosciencesCantor Fitzgerald
Lower Price Target
12/21/2020Acceleron PharmaBarclays
Boost Price Target
12/21/2020Fate TherapeuticsStifel Nicolaus
Boost Price Target
12/17/2020Fate TherapeuticsBarclays
Boost Price Target
12/16/2020Acceleron PharmaMorgan Stanley
Boost Price Target
12/16/2020ExelixisMorgan Stanley
Lower Price Target
12/16/2020Denali TherapeuticsMorgan Stanley
Boost Price Target
12/16/2020Neurocrine BiosciencesMorgan Stanley
Lower Price Target
12/8/2020Fate TherapeuticsMizuho
Boost Price Target
12/7/2020Fate TherapeuticsBMO Capital Markets
Boost Price Target
12/7/2020Fate TherapeuticsWells Fargo & Company
Boost Price Target
12/7/2020Neurocrine BiosciencesWedbush
Lower Price Target
11/16/2020Acceleron PharmaOppenheimer
Boost Price Target
11/12/2020Neurocrine BiosciencesCanaccord Genuity
Lower Price Target
11/11/2020Denali TherapeuticsJPMorgan Chase & Co.
Boost Price Target
11/11/2020Denali TherapeuticsMorgan Stanley
Boost Price Target
11/10/2020Denali TherapeuticsThe Goldman Sachs Group
Boost Price Target
11/10/2020Neurocrine BiosciencesOppenheimer
Lower Price Target
11/10/2020Neurocrine BiosciencesSmith Barney Citigroup
Lower Price Target
11/10/2020Neurocrine BiosciencesWilliam Blair
Reiterated Rating
11/10/2020Neurocrine BiosciencesWedbush
Lower Price Target
11/10/2020Neurocrine BiosciencesCredit Suisse Group
Lower Price Target
11/6/2020Acceleron PharmaMorgan Stanley
Boost Price Target
11/6/2020Acceleron PharmaSVB Leerink
Boost Price Target
11/6/2020Acceleron PharmaHC Wainwright
Boost Price Target
11/6/2020Denali TherapeuticsHC Wainwright
Boost Price Target
10/26/2020ExelixisStifel Nicolaus
Boost Price Target
10/16/2020Denali TherapeuticsWedbush
Boost Price Target
10/16/2020Denali TherapeuticsBTIG Research
Downgrade
10/13/2020Acceleron PharmaMorgan Stanley
Boost Price Target
9/29/2020Acceleron PharmaHC Wainwright
Reiterated Rating
9/22/2020ExelixisMorgan Stanley
Boost Price Target
9/21/2020ExelixisOppenheimer
Boost Price Target
9/21/2020ExelixisPiper Sandler
Boost Price Target
9/14/2020Denali TherapeuticsJPMorgan Chase & Co.
Initiated Coverage
8/24/2020Acceleron PharmaRaymond James
Initiated Coverage
8/24/2020Denali TherapeuticsMorgan Stanley
Boost Price Target
8/20/2020Denali TherapeuticsHC Wainwright
Reiterated Rating
8/14/2020ExelixisWilliam Blair
Reiterated Rating
8/10/2020Denali TherapeuticsWedbush
Reiterated Rating
8/7/2020ExelixisMorgan Stanley
Boost Price Target
7/15/2020ExelixisMorgan Stanley
Boost Price Target
7/8/2020ExelixisSunTrust Banks
Reiterated Rating
6/2/2020ExelixisWilliam Blair
Reiterated Rating
6/1/2020ExelixisOppenheimer
Initiated Coverage
5/14/2020ExelixisSunTrust Banks
Boost Price Target
5/13/2020Denali TherapeuticsNomura
Reiterated Rating
5/6/2020ExelixisBMO Capital Markets
Boost Price Target
5/6/2020ExelixisNeedham & Company LLC
Reiterated Rating
5/6/2020ExelixisPiper Sandler
Boost Price Target
5/6/2020ExelixisMorgan Stanley
Boost Price Target
4/15/2020Denali TherapeuticsMorgan Stanley
Lower Price Target
3/18/2020Denali TherapeuticsCantor Fitzgerald
Reiterated Rating
3/13/2020Denali TherapeuticsEvercore ISI
Upgrade
3/9/2020Denali TherapeuticsNomura Securities
Reiterated Rating
2/28/2020Denali TherapeuticsWedbush
Upgrade
2/24/2020Denali TherapeuticsJefferies Financial Group
Initiated Coverage
2/18/2020Denali TherapeuticsStifel Nicolaus
Initiated Coverage
(Data available from 7/25/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.